These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 33550324)
1. A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China. Wu L; Lai J; Ling Y; Weng Y; Zhou S; Wu S; Jiang S; Ding X; Jin X; Yu K; Chen Y Med Sci Monit; 2021 Feb; 27():e930097. PubMed ID: 33550324 [TBL] [Abstract][Full Text] [Related]
2. Management of Membranous Nephropathy in Western Countries. Alfaadhel T; Cattran D Kidney Dis (Basel); 2015 Sep; 1(2):126-37. PubMed ID: 27536673 [TBL] [Abstract][Full Text] [Related]
3. Management of Membranous Nephropathy in Asia. Xu J; Hu X; Xie J; Chen N Kidney Dis (Basel); 2015 Sep; 1(2):119-25. PubMed ID: 27536672 [TBL] [Abstract][Full Text] [Related]
4. Treatment of primary membranous nephropathy: where are we now? Angioi A; Lepori N; López AC; Sethi S; Fervenza FC; Pani A J Nephrol; 2018 Aug; 31(4):489-502. PubMed ID: 28875476 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents. Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834 [TBL] [Abstract][Full Text] [Related]
6. Detection and clinical significance of glomerular M-type phospholipase A Liu H; Luo W; Gong S; Ding X Intern Med J; 2016 Nov; 46(11):1318-1322. PubMed ID: 27554390 [TBL] [Abstract][Full Text] [Related]
7. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759 [TBL] [Abstract][Full Text] [Related]
8. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China. Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930 [TBL] [Abstract][Full Text] [Related]
9. Treatment of idiopathic membranous nephropathy. Waldman M; Austin HA J Am Soc Nephrol; 2012 Oct; 23(10):1617-30. PubMed ID: 22859855 [TBL] [Abstract][Full Text] [Related]
10. Advances in antigens associated with Idiopathic Membranous Nephropathy. Li SS; Tang DE; Dai Y J Formos Med Assoc; 2021 Nov; 120(11):1941-1948. PubMed ID: 34244038 [TBL] [Abstract][Full Text] [Related]
11. Clinical and Histological Features of Phospholipase A2 Receptor-Associated and Thrombospondin Type-I Domain-containing 7A-Associated Idiopathic Membranous Nephropathy: A Single Center Retrospective Study from China. Zhang D; Zou J; Zhang C; Zhang W; Lin F; Jiang G Med Sci Monit; 2018 Jul; 24():5076-5083. PubMed ID: 30032157 [TBL] [Abstract][Full Text] [Related]
12. [Membranous nephropathy: Diagnosis, new insights in pathophysiology, and therapeutic approach]. Dahan K Rev Med Interne; 2016 Oct; 37(10):674-679. PubMed ID: 27236434 [TBL] [Abstract][Full Text] [Related]
13. [Modern view on treatment of membranous nephropathy]. Bobkova IN; Kamyshova ES Ter Arkh; 2020 Jul; 92(6):99-104. PubMed ID: 33346502 [TBL] [Abstract][Full Text] [Related]
14. Overview of current and alternative therapies for idiopathic membranous nephropathy. Tran TH; J Hughes G; Greenfeld C; Pham JT Pharmacotherapy; 2015 Apr; 35(4):396-411. PubMed ID: 25884528 [TBL] [Abstract][Full Text] [Related]
15. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years? Stai S; Lioulios G; Christodoulou M; Papagianni A; Stangou M J Nephrol; 2023 Mar; 36(2):551-561. PubMed ID: 36450999 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027 [TBL] [Abstract][Full Text] [Related]
18. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. Chen A; Frank R; Vento S; Crosby V; Chandra M; Gauthier B; Valderrama E; Trachtman H BMC Nephrol; 2007 Aug; 8():11. PubMed ID: 17683621 [TBL] [Abstract][Full Text] [Related]
19. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor. Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972 [TBL] [Abstract][Full Text] [Related]
20. Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients. Liu Y; Li X; Ma C; Wang P; Liu J; Su H; Zhuo H; Kong X; Xu D; Xu D Clin Chim Acta; 2018 Jan; 476():9-14. PubMed ID: 29126817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]